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Vaping-Associated Respiratory Distress 
Syndrome: Case Classification and  
Clinical Guidance
Craig M. Lilly, MD1–5; Shahzad Khan, MD1,4,5; Kathryn Waksmundzki-Silva, MD1,4,5;  
Richard S. Irwin, MD1,4–6
Objectives: Exposure to vaping is associated with a growing list of 
respiratory syndromes including an acute progressive form with life-
threatening hypoxemic respiratory failure and pathologic changes of 
lung injury termed vaping-associated respiratory distress syndrome.
Data Sources : Center from Disease Control, Departments of Public 
Health, MEDLINE (via PubMed), and the Cochrane Library.
Study Selection, Data Extraction and Data Synthesis: Cases, series, 
and public health reports of cases that met the Centers for Disease 
Control and Prevention case definition of vaping-associated respi-
ratory disease were extracted by an author with perfect verification 
by a second. Cases were classified on the basis of toxin exposure, 
symptoms, oxygen saturation, progression to respiratory failure, and 
pathologic features, and a clinically actionable system of classifica-
tion was based on expert opinion.
Conclusions: The reported spectrum of vaping-associated respiratory 
diseases allows clinical classification of cases into groups with dis-
tinct evaluation, management, and recommendations for prevention 
and follow-up. Clinical stratification also identifies a small proportion 
of vaping-exposed patients who are at risk for progression to hypox-
emic respiratory failure and an acute respiratory distress syndrome–
like illness.
Key Words: acute respiratory distress syndrome; e-cigarette; 
respiratory failure; review; vape
Our understanding of the widening spectrum, large num-ber of vaping-exposed individuals (1), increasing num-ber of probable and confirmed cases (2), and mortality 
risks of vaping-related respiratory syndromes (3) has generated 
growing public health responses (4) including the enforcement of 
the Massachusetts ban on vaping shops and sales (5). Among the 
most concerning aspects of the growing number of reports of vap-
ing-related respiratory disease (6–8) is that some victims experi-
ence rapid progression to hypoxemic respiratory failure and death 
(3, 8). A recent Centers for Disease Control and Prevention (CDC) 
advisory reported that among 2,016 cases, there were 42 deaths 
from 24 states (4).
The spectrum of the impact of vaping on patients ranges from 
anxiety about the health risks or costs of addiction to progressive 
symptoms of a life-threatening disorder. Our recommendations 
for management are based on the presence of vaping exposure and 
clinical findings that allow cases to be placed into three groups 
with distinct evaluation and management care plan goals and 
strategies. This framework helps critical care professionals quan-
tify vaping exposure and efficiently identify patients at high risk for 
developing respiratory failure. We propose the term “vaping-asso-
ciated respiratory distress syndrome” (VARDS) for symptomatic 
vaping-exposed hypoxemic patients who also have an abnormal 
chest imaging study. We also offer management suggestions for 
the sub-group of vaping-exposed patients who meet the case defi-
nition for the acute respiratory distress syndrome (ARDS) (3).
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SCREENING AND RISK STRATIFICATION
Patients with a history of vaping in the last 90 days (CDC case 
definition) (9) should receive services based on their symptoms 
and preferences. Patients with recent exposure to vaping fumes 
and symptoms that can be caused by vaping and are not attribut-
able to other causes have indications for a chest imaging study and 
screening oximetry. The presence or absence of infiltrates, vaping-
associated symptoms, and normal or abnormal oxygen saturation 
allows triage according to the strata presented in Table 1. We offer 
this classification scheme as a clinically actionable expert opinion-
based starting point for validation studies.
CDC CASE DEFINITION
The CDC has proposed the following four required criterion for 
public health reporting of confirmed e-cigarette or vaping prod-
uct use associated lung injury (EVALI) (4) cases (9): 1) Using an 
e-cigarette (vaping) or dabbing during the 90 days before symp-
tom onset; 2) having a pulmonary infiltrate, such as opacities on 
plain film chest radiograph or ground-glass opacities on chest CT; 
3) the absence of clinical evidence of a pulmonary infection on 
initial work-up: Minimum criteria include negative respiratory 
viral panel, influenza polymerase chain reaction, or rapid test if 
local epidemiology supports testing. All other clinically indi-
cated respiratory infectious disease testing (e.g., urine antigen for 
Streptococcus pneumoniae and Legionella, sputum culture if pro-
ductive cough, bronchoalveolar lavage culture when indicated, 
blood cultures, HIV–related opportunistic respiratory infections 
when appropriate) must be negative; and 4) no medical record 
evidence of alternative plausible diagnoses (e.g., cardiac, rheuma-
tologic, or neoplastic process).
DEFINING VAPING EXPOSURE
A positive response to a query about personal exposure to e-cig-
arette or vaping fumes should be followed by ascertainment of 
the type of electronic nicotine delivery system (ENDS) and the 
method of exposure (device aerosolized or applied by dabbing 
or dripping). Vaping devices have evolved from first generation 
of cig-a-like products that are powered by rechargeable batteries 
and store vaping solutions in replaceable cartridges (cartomiz-
ers), to second generation mid-size electronic cigarettes, to third 
generation advanced personal mechanical modifiable vaporizers, 
to fourth generation regulated modifiable devices. Solution deliv-
ery can be from an internal single or multifill chamber or from 
an attached reservoir. Regulated and direct coil delivery gener-
ally causes higher levels of exposure because they generate denser 
aerosols than fixed delivery methods and generate droplets of 
larger size that can also damage segmental airways. The composi-
tion of the solution(s) that were vaporized should be determined 
including the medium chain triglyceride, glycol-, or glycerine-
based streaming agents, lecithin, vitamin E, or terpene-based 
solvent, the active agent, and any adulterants that were applied to 
herbal ingredients. Available solutions include those that admin-
ister nicotine, nicotine salts, cannabidiol, tetrahydro-cannabinol 
(THC), synthetic cannabinoids, a mix of cannabinoids, and fla-
vorants. A lexicon of terms to enable effective communication 
about exposure is available as supplemental data (Supplemental 
Digital Content 1, http://links.lww.com/CCX/A141).
Individuals who are addicted or choose to vape should be 
encouraged to retain the packing materials and sales receipts 
they received at the time of product purchase and to bring these 
materials when they seek medical care. The date of first exposure, 
vaping frequency, and the type of device allow estimation of total 
exposure. The CDC recommends that the collection of vaping 
solutions should be coordinated with local public health depart-
ments by a qualified toxicology laboratory (4) and must be done in 
strict compliance with local and federal statutes that regulate the 
transportation of these substances.
RISK GROUP STRATIFIED EVALUATION AND 
MONITORING
Low risk asymptomatic patients (group 1) who are concerned 
about the health risks or economic burdens of vaping should 
be encouraged to accept help to escape addiction. The optimal 
approach is individualized based on whether the patient is among 
the 13% of the recently vaping-exposed who exclusively inhale 
nicotine-containing products, the 32% who exclusively inhale 
TABLE 1. Worcester Vaping Clinical Classification System 
Worcester group 1
 Individuals who have been exposed to vaping device fumes in the last 90 d and are free of symptoms of cough, chest pain, weight loss, 
fatigue, and dyspnea.
Worcester group 2
 Individuals who have been exposed to vaping device fumes in the last 90 d and have symptomsa of cough, chest pain, weight loss, fatigue, 
or dyspnea and have resting oxygen saturation of 95% or more and levels of 88% or more with exercise or are near their abnormal 
baseline levels.
Worcester group 3
 Individuals who have been exposed to vaping device fumes in the last 90 d and have symptomsa of cough, chest pain, weight loss, fatigue, 
or dyspnea that are rapidly progressive or have resting oxygen saturation of <95% or levels of <88% with exercise or are below their 
abnormal baseline levels.
aThat are not attributable to other conditions.
Review Article
Critical Care Explorations www.ccejournal.org 3
THC containing products, or the 55% that are exposed to both or 
other substances (10).
Vaping-exposed patients with symptoms of cough, chest 
pain, weight loss, fatigue, or dyspnea of any severity who are not 
explained by other conditions meet the CDC case definition for 
suspected EVALI (4). They require evaluation, and the case may 
need to be reported. When these patients have a resting oxygen 
saturation of 95% or more and levels of 88% or more with exercise 
or levels of oxygen saturation that are near their abnormal baseline 
levels, they are in group 2 and at an intermediate level of risk. It is 
acceptable to perform additional testing at an outpatient facility 
with the expectation that they will seek urgent evaluation should 
they develop significant dyspnea or experience progression of 
their symptoms.
The hypoxemic patients of group 3 are at the highest risk for 
progressing to respiratory failure and require inpatient oximetry 
monitoring and prevention of additional exposure for at least the 
first 48 hours to detect, prevent, and manage progressive hypox-
emia and have urgent intervention should they progress to respi-
ratory failure (Fig. 1). We consider patients who have the three 
CDC defining criteria for EVALI and 4) a chest imaging study 
with new and otherwise unexplained lung abnormalities and 5) 
have acute hypoxemia defined as a decrement from baseline to a 
resting oxygen saturation of less than 95% at rest or less than 88% 
with exercise to have VARDS.
RISK STRATA–GUIDED DIAGNOSTIC TESTING
The low risk asymptomatic patients of group 1 do not require 
vaping-directed diagnostic testing until they develop chest pain, 
weight loss, fatigue, or dyspnea that are not explained by other 
conditions. The presence of respiratory symptoms and hypoxemia 
after exposure to a toxin is an indication for urgent evaluation that 
includes chest imaging and oximetry. When the chest radiograph 
is normal or minimally abnormal, other diseases that produce 
hypoxemia such as pulmonary venous thromboembolism should 
be carefully considered (Fig. 2). The evaluation of group 2 and 3 
patients is guided by the results of oximetry and chest radiogra-
phy. Risk of adverse outcomes is lower for patients with normoxia 
than those with acute hypoxemia and lower for those with normal 
compared with abnormal radiographs.
The key feature of making a diagnosis of EVALI or VARDS 
is the attribution of symptoms to vape fume exposure rather 
than to another condition. Accurate diagnosis requires clinical 
skill, accurate radiographic interpretation, thoughtful selection 
of laboratory and diagnostic testing, and both inclusionary and 
exclusionary reasoning. Recent exposure to other toxins or indi-
viduals with febrile respiratory illnesses, lack of vaccination when 
symptoms develop during a viral endemic season, the presence of 
fevers, chills, or localizing signs of infection, and clustering with 
non-fume exposed cases suggest respiratory tract infection as the 
cause of respiratory symptoms. Exposure to immunosuppressive 
medications or HIV risk factors also suggests that an opportu-
nistic infection may be present. The presence of an inflammatory 
condition or features of a rheumatological disease suggests that 
the symptoms may not be attributable to vaping.
Because vaping-related toxins often cause coincident gastroin-
testinal symptoms including abdominal pain, nausea, vomiting, 
and diarrhea, their occurrence near the time of respiratory symp-
toms favors attribution to vaping. Case clustering around a com-
mon vape juice is a strong inclusionary factor. The association of 
symptoms with abnormal respiratory system physical findings is 
an indication for radiological evaluation.
Non-specific inclusionary laboratory markers include leu-
kocytosis, elevated liver function tests, abnormal inflammatory 
Figure 1. Symptom- and oximetry-based risk stratification allows identification of patients with indications for monitoring.
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markers such as erythrocyte sedimentation rate or C-reactive 
protein and oil-red-O staining of sputum pneumocytes for fat 
containing cells. Exclusionary factors include positive respira-
tory viral or influenza tests, Legionella and Pneumococcal urinary 
antigen tests, positive fungal markers, sputum Gram stain demon-
strating neutrophils and bacteria or the presence of microbes in 
sputum or blood cultures.
Tissue-directed phenotyping should be considered when chest 
imaging demonstrates substantial bilateral abnormalities, and 
infectious or inflammatory causes have not been ruled out. Chest 
CT can provide details that can direct the acquisition of respira-
tory tract cultures and tissue. It can also suggest a fibrotic pheno-
type that has been associated with giant-cell interstitial pneumonia 
(11) when cobalt, lead, or another heavy metal has been released 
from an ENDS heating coil (12).
Series of chest CT studies of patients with rapidly progressive 
or subacute vaping-associated respiratory disease (12) have dis-
played a variety of patterns including those associated with acute 
eosinophilic pneumonia (13), diffuse alveolar damage, organiz-
ing pneumonia (12), endogenous lipoid pneumonia, giant-cell 
interstitial pneumonia (12), hypersensitivity pneumonitis (14), 
lipoid pneumonia (15), and diffuse alveolar hemorrhage (16). The 
enhanced definition of the anatomic distribution of abnormal tis-
sue helps to define the optimal site for obtaining respiratory sys-
tem cultures, cells, and tissues.
When infection has not been excluded or the patient is immu-
nocompromised and at risk for opportunistic infections, a bron-
choscopic sampling for cultures, cells studies, and laboratory 
testing can be helpful. Bronchoscopic examination of the airways 
can also identify airway mucosal injury and epithelial disruption 
caused by the inhalation of the heated toxins that are present in 
vape fumes (see below).
Acute eosinophilic pneumonia is suggested when greater than 
25% of the cells recovered from bronchoalveolar lavage fluid 
(BAL) are eosinophils (17), and the hypersensitivity pneumonitis 
phenotype is suggested when the CD4/CD8 ratio of BAL lympho-
cytes is less than 1 (18). Analysis of BAL cells can also identify 
patients with exogenous lipoid pneumonia from the ingestion of 
lipids and endogenous lipoid pneumonia produced in response 
to tissue injury in the setting of airway obstruction from patients 
with other phenotypes.
Oil-red-O staining of lower airway histiocytes (alveolar macro-
phages or pneumocytes) is a well-known technique that is being 
explored in the context of vaping (19). Based on our original 
description of how this technique best distinguishes lipoid pneumo-
nia from other forms of lung disease (20), we believe that using the 
quantitative lipid laden alveolar macrophage index (range 0–400) 
with a cut off value of 100 would better separate lipoid pneumonia 
cases from patients with other pathologies than the qualitative posi-
tive percentage technique (20). We found that combining a staining 
intensity measure with lipid positive percentage provided superior 
discriminatory power when 100 cells were counted.
Pathologic examination of open or bronchoscopically obtained 
biopsies allows identification of granulomatous (21), fibrotic, 
eosinophilic, hemorrhagic, and acute lung injury architectures. 
The focus on lipoid pneumonia as a pathologic phenotype for 
patients with subacute presentation of vaping-related respiratory 
disease has recently been expanded to include lung injury pathol-
ogies by examination of patients who presented with progressive 
dyspnea, cough, chest pain, fatigue, weight loss, hypoxemia with 
progression to respiratory failure. These patients were found to 
have histopathologic changes of acute lung injury, including acute 
fibrinous pneumonitis, diffuse alveolar damage, usually bronchi-
olocentric organizing pneumonia, and bronchiolitis (3).
Figure 2. Evaluation of group 2 and 3 patients based on oximetry and chest radiography. *Reporting is strongly recommended and is required by some public 
health departments.
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Different toxins generated by the heating of the mix of fla-
vorants, aldehyde or alcohol-based solvents, tocopherols, hydro-
carbon-based oils, and adulterants delivered at doses that vary by 
alternative vaping techniques are expected to produce a spectrum 
of respiratory tissue responses. The increasingly broad spectrum 
of clinical, radiographic, and pathologic presentations strongly 
implies that vaping produces a variety of respiratory syndromes. It 
is increasingly clear that the vaping-related respiratory syndromes 
include alternative pathologic phenotypes including lipoid (22), 
acute eosinophilic pneumonia (13), hypersensitivity pneumonitis 
(14), and acute lung injury variants (3, 7).
The current CDC guidance documents acknowledge that spe-
cialist consultation is helpful and pathologic examination of respi-
ratory tract tissues is indicated when recommended by a specialist 
(4). Phenotypic specificity is helpful for distinguishing cases that 
are likely to benefit from early treatment with steroids (lipoid 
pneumonia, acute eosinophilic pneumonia, and hypersensitivity 
pneumonitis) from the tissue injury variants that may be harmed 
by the immunosuppressive side effects of steroids and phenotypes 
destined for recovery with avoidance of exposure alone.
RISK GROUP–GUIDED MANAGEMENT AND 
PREVENTION PLANS
Group 1 (asymptomatic) patients who affirm a desire to quit 
vaping should be offered addiction medicine support for sub-
stance-directed treatment. There is evidence that patients who 
have addiction to THC or nicotine-containing products can ben-
efit from cognitive-behavioral therapy, contingency management, 
motivational enhancement therapy, and multidimensional family 
therapy (4, 23, 24).
Normoxic, asymptomatic patients with abnormal radiographs 
should have a therapeutic trial of vaping cessation and evaluation 
for other conditions that may be responsible for their symptoms 
(Fig. 2). Hypoxic patients with normal pulmonary imaging studies 
should be evaluated for alternative explanations for their symp-
toms such as pulmonary or fat embolism. These patients require 
close follow-up for deterioration, and specialist evaluation is rec-
ommended when hypoxemia persists. Unlike patients with abnor-
mal chest radiographs, public health reporting is not currently 
recommended or required for patients with normal radiographs.
Group 2 patients who are normoxic, symptomatic, and have 
abnormal chest imaging should be carefully examined for evi-
dence of infection. More precise anatomic definition of the 
abnormalities evaluated by chest CT should be considered when 
risk factors for neoplastic disease, including significant tobacco 
exposure, are present or when radiographic abnormalities are 
extensive. Spirometry is indicated for those with severe, persis-
tent, or progressive shortness of breath. Group 2 patients should 
be encouraged to promptly report progression of their symptoms 
and should be followed to resolution of their symptoms and radio-
graphic abnormalities.
Defining when a combination of clinical, radiographic, and 
pathologic features strongly implicates the presence of specific 
diagnosis is fundamental to deciding to prescribe immunosup-
pressives or to focus on cessation of exposure will best promote 
respiratory tissue healing from the toxins. In order to expand the 
range of therapeutic options, we present a case of vaping-associ-
ated airway injury associated with improvement after the removal 
of necrotic tissue that was obstructing the airways that subtended 
the infiltrates.
REPORT OF AN AIRWAY TISSUE INJURY 
VARIANT VARDS CASE
A 29-year-old man with a history of polysubstance abuse includ-
ing cocaine, marijuana, and cigarettes presented with the acute 
onset of pleuritic chest pain and progressive dyspnea on exertion 
24–48 hours after consuming alcohol, nasally insufflating cocaine, 
vaping an oil-based THC containing solution followed by loss of 
consciousness. On arrival to the hospital, the patient was found 
to have sinus tachycardia and acute hypoxemic respiratory failure 
with a chest CT demonstrating bilateral lower zone predominant, 
nodular infiltrates centered around airways, and a segmental pul-
monary embolism. His urinary toxicology screen was positive for 
cannabinoids, and a HIV test was negative. The patient was man-
aged with oxygen, anticoagulation, and was evaluated with a bron-
choscopic examination of his airways.
The airways that subtended both abnormal lower zone opacities 
were covered with opaque necrotic material that was removed by 
suction (Fig. 3). The BAL fluid demonstrated neutrophils without 
eosinophils or lipid laden pneumocytes. Cultures were all sterile. 
His procedure was associated with rapid resolution of his symp-
toms and resolution of his hypoxemia. The patient subsequently 
achieved complete functional recovery, and he has abstained from 
vaping.
The endoluminal findings of airway occlusion from vaping 
fume-related necrotic debris accumulation suggest that vaping can 
cause one of the defining features of endogenous lipoid pneumo-
nia, that is, airway obstruction (25). This case of early intervention 
to remediate airway occlusion and rapid physiologic improvement 
has led to the hypothesis that expeditious opening of the airways 
can interrupt the progression to the deranged endogenous lipid 
metabolism (26) that has been observed in the mouse model of 
endogenous lipoid pneumonia.
In addition to the two low lipid phenotype patients of the prior 
report (19), this case also demonstrates that patients with the 
airway injury predominant phenotype can rapidly improve with 
airway clearance, high-flow oxygen, non-invasive ventilation, and 
heal to an optimal outcome without being exposed to immuno-
suppressive anti-inflammatory medications.
Risk group 3 patients require monitoring for progressive symp-
toms and serial or continuous oximetry to detect worsening hypox-
emia and effective measures to prevent exposure to vaping fumes. 
Airway clearance techniques such as cough encouragement and 
prevention of atelectasis with incentive spirometry and conserva-
tive fluid management strategies should be used to prevent pro-
gression to respiratory failure. Falling oxygen saturation should 
be managed with escalation of oxygen therapies, with the appli-
cation of a high-flow system, before moderate hypoxemia is pres-
ent. Inhaled bronchodilators should be prescribed to patients with 
wheezing or documented obstructive deficits. Patients with elevated 
respiratory rates should be managed with non-invasive ventilation 
before hypercarbia is present, and invasive mechanical ventilation is 
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indicated for those who present with or progress to respiratory fail-
ure. Because severe vaping cases share clinical and pathologic fea-
tures with ARDS (3), we favor conservative fluid management and 
a lung-protective ventilation strategy. We prefer a volume-targeted 
mode with a tidal volume goal of 6 cc/kg and a plateau pressure of 
less than 30 cm water when it achieves adequate gas exchange. We 
recommend pressure-controlled ventilation and paralysis be con-
sidered when volume-targeted ventilation is not effective. When 
oxygenation is inadequate, we recommend considering inhaled 
epoprostenol or nitric oxide, prone position ventilation, and con-
sideration of rescue with extracorporeal membrane oxygenation. 
Parenteral steroids should be considered for all patients with pro-
gressive hypoxemic respiratory failure particularly when other 
etiologies have been ruled out and contra-indications are not iden-
tified. In addition, measures should be taken to prevent exposure 
by others to any remaining vaping solution that has been associated 
with a case of hypoxemic respiratory failure.
Those with steroid sensitive phenotypes including acute eosin-
ophilic pneumonia, hypersensitivity pneumonia, and lipoid pneu-
monia should be treated promptly with a course of steroids. We 
recommend that patients without signs of respiratory failure or 
are improving and do not have evidence of a steroid sensitive phe-
notype be managed without exposure to immunosuppressives.
Group 3 patients should have spirometry at a time when they are 
able to perform the required maneuvers. These patients require fol-
low-up to the resolution of symptoms, clearing of their radiographic 
abnormalities, and normalization of their spirograms. Patients who 
have difficulty with cessation of vaping should be encouraged to 
accept help from an addiction medicine professional.
We must work with our patients to better identify the sub-
stances that they are vaping and develop culturally effective meth-
ods for encouraging abstinence. We must not attribute to vaping 
respiratory illnesses that are caused by infections. Our approach 
to the needs of patients who are exposed to vaping fumes should 
be guided by their symptoms, physical findings, gas exchange, 
radiographic abnormalities, and preferences. We should use 
anti-inflammatories when there is evidence of a steroid sensitive 
condition and avoid steroids when abstinence results in rapid 
improvement. Those at risk for acute respiratory failure must be 
identified, monitored, evaluated, and treated.
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